Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Biosyst ; 13(8): 1432-1437, 2017 Jul 25.
Article in English | MEDLINE | ID: mdl-28685788

ABSTRACT

Type 1 diabetes is associated with such complications as blindness, kidney failure, and nerve damage. Replacing C-peptide, a hormone normally co-secreted with insulin, has been shown to reduce diabetes-related complications. Interestingly, after nearly 30 years of positive research results, C-peptide is still not being co-administered with insulin to diabetic patients. The following review discusses the potential of C-peptide as an auxilliary replacement therapy and why it's not currently being used as a therapeutic.


Subject(s)
C-Peptide/therapeutic use , Diabetes Complications/therapy , Diabetes Mellitus, Type 1/therapy , Insulin/therapeutic use , Animals , Bibliometrics , C-Peptide/deficiency , C-Peptide/history , C-Peptide/pharmacokinetics , Clinical Trials as Topic , Diabetes Complications/history , Diabetes Complications/metabolism , Diabetes Complications/pathology , Diabetes Mellitus, Type 1/history , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 1/pathology , Disease Models, Animal , History, 20th Century , History, 21st Century , Humans , Insulin/deficiency , Insulin/history , Insulin-Secreting Cells/metabolism , Insulin-Secreting Cells/pathology , Iron/metabolism , Protein Binding , Serum Albumin/metabolism , Serum Albumin/pharmacokinetics , Zinc/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...